{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:24:56Z","timestamp":1772778296266,"version":"3.50.1"},"reference-count":28,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Respiratory J"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Oral selexipag, a prostacyclin pathway agent (PPA), is effective in patients with pulmonary arterial hypertension (PAH). The objective of this study is to assess the impact of initiating oral selexipag within 12\u2009months of diagnosis on health outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective cohort study used data from Optum's de\u2010identified Clinformatics\u00ae Data Mart Database. PAH patients between 1 October 2015 and 30 September 2019 were included. Patients were also required to have received PAH medication within 12\u2009months of their initial diagnosis. Study groups included patients who initiated selexipag within 12\u2009months of PAH diagnosis (SEL\u2009\u2264\u200912) and those who did not initiate any PPA within 12\u2009months of PAH diagnosis (No PPA\u2009\u2264\u200912). Inverse probability of treatment weighting was used to remove potential confounding between groups. Cox and Poisson regression models were used to compare hospitalization and disease progression. Generalized linear model with gamma distribution and log link was used to compare costs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>SEL\u2009\u2264\u200912 had lower rate of all\u2010cause hospitalizations (rate ratio: 0.76, 95% confidence interval [CI]: 0.60, 0.96) versus no PPA\u2009\u2264\u200912, but no differences in PAH\u2010related hospitalization rate (rate ratio: 1.03, 95% CI: 0.79, 1.33) or risk of disease progression (hazard ratio: 1.01, 95% CI: 0.71, 1.44). SEL\u2009\u2264\u200912 incurred lower all\u2010cause (mean difference: \u2212$23\u2009623; 95% CI: \u221235\u2009537, \u22128512) and PAH\u2010related total medical costs (mean difference: \u2212$12\u2009927; 95% CI: \u221219\u2009559, \u22125679) versus no PPA\u2009\u2264\u200912.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Selexipag initiation within 12\u2009months of PAH diagnosis demonstrated reductions in all\u2010cause hospitalization rate and medical costs.<\/jats:p><\/jats:sec>","DOI":"10.1111\/crj.13704","type":"journal-article","created":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T11:00:07Z","timestamp":1696676407000},"page":"1209-1222","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of selexipag use within 12\u2009months of pulmonary arterial hypertension diagnosis on hospitalizations and medical costs: A retrospective cohort study"],"prefix":"10.1111","volume":"17","author":[{"given":"Yuen","family":"Tsang","sequence":"first","affiliation":[{"name":"Real\u2010World Value &amp; Evidence Janssen Scientific Affairs, LLC  Titusville New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1822-6214","authenticated-orcid":false,"given":"Michael","family":"Stokes","sequence":"additional","affiliation":[{"name":"Data Analytics Evidera  St\u2010Laurent Quebec Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong\u2010Jin","family":"Kim","sequence":"additional","affiliation":[{"name":"Data Analytics Evidera  St\u2010Laurent Quebec Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Tilney","sequence":"additional","affiliation":[{"name":"Data Analytics Evidera  Waltham Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumeet","family":"Panjabi","sequence":"additional","affiliation":[{"name":"Real\u2010World Value &amp; Evidence Janssen Scientific Affairs, LLC  Titusville New Jersey USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,10,7]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccl.2004.04.004"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01032\u20102015"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003\u20104819\u2010107\u20102\u2010216"},{"key":"e_1_2_11_5_1","unstructured":"American Lung Association.Learn about pulmonary arterial hypertension. 2020. Accessed May 2022.https:\/\/www.lung.org\/lung-health-diseases\/lung-disease-lookup\/pulmonary-arterial-hypertension\/learn-about-pulmonary-arterial-hypertension"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.15\u20100300"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00072709"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.11.030"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003\u20104819\u2010112\u20107\u2010485"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503184"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908\u20101640OC"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2013.08.010"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.10.043"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.165.6.2106079"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735\u20101097(02)02012\u20100"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.01.066"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac237"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201810\u2010672CME"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq433"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0262293"},{"key":"e_1_2_11_21_1","unstructured":"US Bureau of Labor Statistics.CPI inflation calculator2020.https:\/\/www.bls.gov\/data\/inflation_calculator.htm"},{"key":"e_1_2_11_22_1","unstructured":"ClinicalTrials.gov.Selexipag (ACT\u2010293987) in pulmonary arterial hypertension (GRIPHON). NCT01106014.2018. Accessed May 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01106014"},{"key":"e_1_2_11_23_1","unstructured":"ClinicalTrials.gov.The efficacy and safety of initial triple versus initial dual oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension (TRITON). NCT02558231. 2021. Accessed May 2022.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02558231"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab724.1964"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11906\u2010019\u20100950\u2010y"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00123712"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2021.88609"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.117.003973"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.14\u20100193"}],"container-title":["The Clinical Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/crj.13704","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T03:35:09Z","timestamp":1704339309000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/crj.13704"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,7]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1111\/crj.13704"],"URL":"https:\/\/doi.org\/10.1111\/crj.13704","archive":["Portico"],"relation":{},"ISSN":["1752-6981","1752-699X"],"issn-type":[{"value":"1752-6981","type":"print"},{"value":"1752-699X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,7]]},"assertion":[{"value":"2023-05-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}